{"id":"W3203807700","doi":"10.1016/j.annonc.2021.08.1043","title":"521P Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sanofi; Meso Scale Diagnostics; Novartis; AstraZeneca; Amgen","keywords":"Medicine; Dosing; Carcinoembryonic antigen; Conjugate; Pharmacology; Toxicity; Limiting; Monoclonal antibody; Maximum tolerated dose; Pharmacokinetics; Antibody; Oncology; Internal medicine; Cancer; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009160042,0.00105827,0.002114561,0.0005105104,0.0003163739,0.0009614716,0.0006315585,0.0009064314,0.003947836],"category_scores_gemma":[0.0009612349,0.0006705527,0.001464999,0.0005184262,0.0008417792,0.000957808,0.0003544306,0.003551198,0.0007380283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009847695,"about_ca_system_score_gemma":0.0009063209,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001089581,"about_ca_topic_score_gemma":0.001987817,"domain_scores_codex":[0.9994403,0.000224736,0.0000243164,0.0001262696,0.00004851716,0.0001358942],"domain_scores_gemma":[0.9995401,0.0000954026,0.00008820042,0.00006466588,0.00002117652,0.0001904944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8335953,0.04349297,0.003720773,0.0002765957,0.001192023,0.0001149328,0.0002479596,0.003337526,0.03238364,0.0002581083,0.001341643,0.08003855],"study_design_scores_gemma":[0.261641,0.7067587,0.02129476,0.00002706611,0.0008703856,0.0001697131,0.0001192706,0.002471517,0.004331319,0.0002039686,0.002056034,0.00005622838],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978197,0.0006119402,0.0001666901,0.0001345187,0.00007620895,0.0002235983,0.00022818,0.00003572397,0.0007033346],"genre_scores_gemma":[0.9972709,0.0004382993,0.0003461002,0.0001700478,0.00006490997,0.0002869091,0.0003510736,0.00001368929,0.001058043],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003947836,"threshold_uncertainty_score":0.01320678,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06641753308482397,"score_gpt":0.414233516384368,"score_spread":0.347815983299544,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}